Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Caroline L. Trotter, Nick J. Andrews, Edward B. Kaczmarski, Elizabeth Miller, Mary E. Ramsay*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

515 Citations (Scopus)


The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.

Original languageEnglish
Pages (from-to)365-367
Number of pages3
JournalThe Lancet
Issue number9431
Publication statusPublished - 24 Jul 2004


Dive into the research topics of 'Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction'. Together they form a unique fingerprint.

Cite this